Table 3 |
|||||
|
Comparison of PedACR and ASAS domains after baseline adjustment |
|||||
|
Week 4 |
Week 8 |
Week 12 |
Treatment P-value* |
||
|
|
|||||
|
Physicians' Global |
Adalimumab |
2.97 +/- 0,53 |
2.44 +/- 0.53 |
2.67 +/- 0.54 |
|
|
5.81# |
Placebo |
4.43 +/- 0.57 |
4.43 +/- 0.57 |
4.31 +/- 0.57 |
|
|
Difference (95% confidence Interval) |
-1.47 +/- 0.78 |
-2.00 +/- 0.78 |
-1.64 +/- 0.79 |
0.021 |
|
|
|
|||||
|
Parents' Global |
Adalimumab |
3.45 +/- 0.62 |
2.86 +/- 0.62 |
2.85 +/- 0.63 |
|
|
5.78 |
Placebo |
5.62 +/- 0.66 |
4.75 +/- 0.66 |
5.24 +/- 0.67 |
|
|
Difference (95% confidence Interval) |
-2.17 +/- 0.91 |
-1.89 +/- 0.91 |
-2.39 +/- 0.93 |
0.014 |
|
|
|
|||||
|
No. Active Joints |
Adalimumab |
1.72 +/- 0.49 |
1.31 +/- 0.49 |
1.99 +/- 0.5 |
|
|
4.31 |
Placebo |
2.59 +/- 0.52 |
3.65 +/- 0.52 |
2.83 +/- 0.53 |
|
|
Difference (95% confidence Interval) |
-0.87 +/- 0.72 |
-2.35 +/- 0.72 |
-0.84 +/- 0.73 |
0.032 |
|
|
|
|||||
|
No. LOM Joints |
Adalimumab |
1.60 +/- 0.47 |
1.78 +/- 0.47 |
1.84 +/- 0.48 |
|
|
3.34 |
Placebo |
2.38 +/- 0.50 |
2.65 +/- 0.50 |
2.01 +/- 0.52 |
|
|
Difference (95% confidence Interval) |
-0.78 +/- 0.69 |
-0.87 +/- 0.69 |
-0.17 +/- 0.71 |
0.198 |
|
|
|
|||||
|
CHAQ |
Adalimumab |
0.57 +/- 0.12 |
0.42 +/- 0.12 |
0.44 +/- 0.12 |
|
|
0.98 |
Placebo |
0.80 +/- 0.12 |
0.75 +/- 0,12 |
0.74 +/- 0.13 |
|
|
Difference (95% confidence Interval) |
-0.22 +/- 0.17 |
-0.34 +/- 0.17 |
-0.30 +/- 0.17 |
0.079 |
|
|
|
|||||
|
CRP |
Adalimumab |
0.99 +/- 2.77 |
3.92 +/- 2.77 |
1.98 +/- 2.89 |
|
|
10.34 |
Placebo |
5.91 +/- 3.05 |
8.69 +/- 3.05 |
9.72 +/- 3.05 |
|
|
Difference (95% confidence Interval) |
-4.92 +/- 4.14 |
-4.76 +/- 4.14 |
-7.74 +/- 4.23 |
0.103 |
|
|
|
|||||
|
Spinal inflammation |
Adalimumab |
2.60 +/- 0.56 |
2.64 +/- 0.56 |
2.05 +/- 0.56 |
|
|
4.73 |
Placebo |
3.56 +/- 0.60 |
3.51 +/- 0.60 |
3.50 +/- 0.60 |
|
|
Difference (95% confidence Interval) |
-0.97 +/- 0.83 |
-0.87 +/- 0.83 |
-1.45 +/- 0.83 |
0.179 |
|
|
|
|||||
|
Pain Score |
Adalimumab |
3.60 +/- 0.59 |
3.60 +/- 0.59 |
3.23 +/- 0.60 |
|
|
5.84 |
Placebo |
4.38 +/- 0.63 |
3.98 +/- 0.63 |
4.33 +/- 0.64 |
|
|
Difference (95% confidence Interval) |
-0.78 +/- 0.87 |
-0.38 +/- 0.87 |
-1.11 +/- 0.88 |
0.360 |
|
|
|
|||||
|
Patients' Global |
Adalimumab |
4.50 +/- 0.54 |
3.97 +/- 0.54 |
3.76 +/- 0.55 |
|
|
6.38 |
Placebo |
5.44 +/- 0.58 |
4.70 +/- 0.58 |
4.82 +/- 0.59 |
|
|
Difference (95% confidence Interval) |
-0.94 +/- 0.80 |
-0.74 +/- 0.80 |
-1.06 +/- 0.81 |
0.210 |
|
|
|
|||||
|
BASFI |
Adalimumab |
2.53 +/- 0.47 |
2.38 +/- 0.47 |
2.14 +/- 0.48 |
|
|
4.00 |
Placebo |
3.36 +/- 0.50 |
3.28 +/- 0.50 |
3.09 +/- 0.51 |
|
|
Difference (95% confidence Interval) |
-0.84 +/- 0.69 |
-0.90 +/- 0.69 |
-0.95 +/- 0.70 |
0.171 |
|
|
|
|||||
|
*Total treatment difference, repeated measurement design. # Baseline adjusted value. $ ANCOVA analysis. |
|||||
|
Horneff et al. Arthritis Research & Therapy 2012 14:R230 doi:10.1186/ar4072 |
|||||
